Taken together, all these findings illustrated that DUSP22 could alleviate lipid accumulation, inflammation, hepatic fibrosis, and NASH-HCC progression, primarily relying on the FAK inactivation. The gene discussed is DUSP22; the disease is metabolic dysfunction-associated steatohepatitis.